Welcome to LookChem.com Sign In|Join Free

CAS

  • or

67-96-9

Post Buying Request

67-96-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

67-96-9 Usage

Description

Dihydrotachysterol is a synthetic analog of vitamin D. It is considered as a reduction product of vitamin D2 (ergocalciferol). It stimulates bone mineralization as well as calcium and phosphorus absorption in intestine. Dihydrotachysterol has been used for the treatment of hypoparathyroidism, osteomalacia, osteoporosis, low calcium level, and kidney osteodystrophy. Though dihydrotachysterol is more expensive, dihydrotychysterol therapy is preferred as it has a more rapid onset of action (1-7 d) and a shorter time for dissipation of effect in the event of toxicity (2-3 weeks) than vitamin D2.

Pharmacodynamics

Dihydrotachysterol is hydroxylated in the liver to 25-hydroxydihydrotachysterol, which is the major circulating active form of the drug. It does not undergo further hydroxylation by the kidney and therefore is the analogue of 1,25-dihydroxyvitamin D. Dihydrotachysterol is effective in the elevation of serum calcium by stimulating intestinal calcium absorption and mobilizing bone calcium in the absence of parathyroid hormone and of functioning renal tissue. It also increases renal phosphate excretion. In contrast to parathyroid extract, dihydrotachysterol is active when taken orally, exerts a slow but persistent effect, and may be used for long periods without increasing the dosage or causing tolerance. Dihydrotachysterol is faster-acting than pharmacologic doses of vitamin D and is less persistent after cessation of treatment, thus decreasing the risk of accumulation and of hypercalcemia.

Indication

Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).

Uses

Different sources of media describe the Uses of 67-96-9 differently. You can refer to the following data:
1. Dihydrotachysterol is a form of vitamin D. Vitamin D is a fat-soluble vitamin and has properties of both vitamins and minerals. Vitamin D helps you to absorb calcium from what you eat. You need calcium to keep your bones strong, and to help your muscles and nerves work properly. The term Vitamin D collectively refers to a group of structurally similar chemicals and their metabolites, which includes alfacalcidol (1 α hydroxycholecalciferol), calcitriol (1,25-dihydroxychole-calciferol), cholecalciferol (Vitamin D3), dihydrotachysterol(DHT) and ergocalciferol (Vitamin D2). These agents have antirachitic properties. Dihydrotachysterol-2 (DHT-2) is a vitamin D2 analog for the Pharmaceutical industry. Dihydrotachysterol-2 is used in the prevention and treatment of several bone growth disorders such as osteoporosis. Besides this the substance is also used to treat several abnormalities of the parathyroid glands such as hypoprathyroidism.
2. Calcium regulator. Preparation by reduction of Tachysterol. It is widely used for hypocalcemic hypoparathyroidism following surgical removal of parathyroids.

References

https://en.wikipedia.org/wiki/Dihydrotachysterol https://www.drugbank.ca/drugs/DB01070 https://pubchem.ncbi.nlm.nih.gov Jack Z. Yetiv and Joseph R. Bianchine, Hypertension, Cardiovascular Disease, Analgesics, and Endocrine Disorders, 1981, ISBN 0-12-788950-7 Carl P. Weiner and Kate Rope, The Complete Guide to Medications During Pregnancy and Breastfeeding, 2013, ISBN-10: 0312676468

Chemical Properties

White Solid

Originator

Hytakerol,Winthrop,US,1950

Definition

ChEBI: A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.

Manufacturing Process

The process of isolating chemically uniform crystalline dihydrotachysterol comprises subjecting the solution of the crude hydrogenation product of tachysterol in benzine to chromatographic adsorption by means of active aluminum oxide while collecting the components having a minor tendency of being adsorbed, subjecting the said components to a repeated chromatographic adsorption and converting the components having a minor tendency of being adsorbed into its ester by treatment with acetic anhydride in pyridine solution, isolating the ester formed from the reaction mixture, subjecting its solution in benzine to chromatographic adsorption while collecting the components having a minor tendency of being adsorbed, recrystallizing these components, saponifying the crystalline ester and recrystallizing the dihydrotachysterol obtained.

Brand name

Hytakerol (Sterling Winthrop).

Therapeutic Function

Blood calcium regulator

Veterinary Drugs and Treatments

DHT is used in small animals to treat hypocalcemia secondary to hypoparathyroidism or severe renal disease.

Purification Methods

Crystallise the sterol from 90% MeOH, UV: max at 242, 251 and 261nm (E1% 760, 1010 and 650) in EtOH. The acetate has m108-110o and [] +32.8o (CHCl3), UV: max at 242, 251 and 261nm (E 780, 910 and 600) in EtOH. The propionate has m 97-98o and [] +37o (CHCl3), UV: max 242, 251 and 261nm (E 750, 860 and 570) in EtOH. [Werder Hoppe Seyler's Z Physiol Chem 260 119 1939, Windaus et al. Justus Liebigs Ann Chem 499 1978 1932, Beilstein 6 III 2833, 6 IV 3994, 4161.]

Check Digit Verification of cas no

The CAS Registry Mumber 67-96-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 7 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 67-96:
(4*6)+(3*7)+(2*9)+(1*6)=69
69 % 10 = 9
So 67-96-9 is a valid CAS Registry Number.
InChI:InChI=1/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+

67-96-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (Y0000544)  Dihydrotachysterol  European Pharmacopoeia (EP) Reference Standard

  • 67-96-9

  • Y0000544

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000482)  Dihydrotachysterol for system suitability  European Pharmacopoeia (EP) Reference Standard

  • 67-96-9

  • Y0000482

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (D9257)  Dihydrotachysterol  analytical standard

  • 67-96-9

  • D9257-50MG

  • 1,765.53CNY

  • Detail
  • USP

  • (1204000)  Dihydrotachysterol  United States Pharmacopeia (USP) Reference Standard

  • 67-96-9

  • 1204000-4X30MG

  • 4,662.45CNY

  • Detail

67-96-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name dihydrotachysterol

1.2 Other means of identification

Product number -
Other names Dihydrotachysterin2

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:67-96-9 SDS

67-96-9Synthetic route

3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene
51744-66-2

3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene

A

(3S,5E,7E,10R)-9,10-seco-ergosta-5,7,22t-trien-3-ol
65377-91-5

(3S,5E,7E,10R)-9,10-seco-ergosta-5,7,22t-trien-3-ol

B

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
With bis(cyclopentadienyl)titanium dichloride; lithium aluminium tetrahydride In tetrahydrofuran for 2.5h;A 6.5%
B 86%
With bis(cyclopentadienyl)titanium dichloride In tetrahydrofuran; toluene for 1.5h; Ambient temperature;A 38%
B 57%
dihydrotachysterol2 tert-butyldimethylsilyl ether
142980-94-7, 143060-77-9

dihydrotachysterol2 tert-butyldimethylsilyl ether

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran for 1h; Ambient temperature;86%
Calciferol
50-14-6

Calciferol

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
With sodium; butan-1-ol
With pentan-1-ol; sodium
With sodium; glycerol; xylene
With sodium; ethylene glycol; xylene
Multi-step reaction with 2 steps
1: 58 percent / iodine / diethyl ether / 2.5 h
2: 86 percent / LiAlH4, Cp2TiCl2 / tetrahydrofuran / 2.5 h
View Scheme
(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan
67-96-9, 807-27-2, 7665-90-9, 34611-22-8, 62777-58-6, 65377-86-8, 65377-91-5, 116559-85-4, 116559-86-5, 143060-73-5

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
ueber mehrere Stufen;
tachysterol
115-61-7

tachysterol

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
With ammonia; lithium
With sodium; diethylamine
With sodium; N-methylaniline
tachysterol
115-61-7

tachysterol

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

toxisterol2 R
104396-98-7

toxisterol2 R

Conditions
ConditionsYield
With ethanol; sodium
With ethanol; sodium Isolierung als O-Allophanoyl-Derivat;
toxisterol2 R
104396-98-7

toxisterol2 R

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
ueber mehrere Stufen;
tetrachloromethane
56-23-5

tetrachloromethane

Calciferol
50-14-6

Calciferol

ethylene glycol
107-21-1

ethylene glycol

sodium

sodium

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan
67-96-9, 807-27-2, 7665-90-9, 34611-22-8, 62777-58-6, 65377-86-8, 65377-91-5, 116559-85-4, 116559-86-5, 143060-73-5

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan

C

toxisterol2 R
104396-98-7

toxisterol2 R

tetrachloromethane
56-23-5

tetrachloromethane

Calciferol
50-14-6

Calciferol

glycerol
56-81-5

glycerol

sodium

sodium

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan
67-96-9, 807-27-2, 7665-90-9, 34611-22-8, 62777-58-6, 65377-86-8, 65377-91-5, 116559-85-4, 116559-86-5, 143060-73-5

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan

C

toxisterol2 R
104396-98-7

toxisterol2 R

Calciferol
50-14-6

Calciferol

butan-1-ol
71-36-3

butan-1-ol

sodium

sodium

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan
67-96-9, 807-27-2, 7665-90-9, 34611-22-8, 62777-58-6, 65377-86-8, 65377-91-5, 116559-85-4, 116559-86-5, 143060-73-5

(3aR)-3ar-Methyl-3c-((1R:4R)-1.4.5-trimethyl-hexen-(2t)-yl)-7-[2-((2S)-5t-hydroxy-2r-methyl-cyclohexyliden-(seqcis))-aethyliden-(seqtrans)]-(7atH)-hexahydro-indan

C

toxisterol2 R
104396-98-7

toxisterol2 R

5,6-trans-ergocalciferol

5,6-trans-ergocalciferol

A

(3S,5E,7E,10R)-9,10-seco-ergosta-5,7,22t-trien-3-ol
65377-91-5

(3S,5E,7E,10R)-9,10-seco-ergosta-5,7,22t-trien-3-ol

B

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
With Wilkinson's catalyst; benzene Hydrogenation;
O-<3.5-dinitro-4-methyl-benzoyl>-tachysterol2

O-<3.5-dinitro-4-methyl-benzoyl>-tachysterol2

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

toxisterol2 R
104396-98-7

toxisterol2 R

Conditions
ConditionsYield
With propan-1-ol; sodium
With propan-1-ol; sodium Isolierung als O-Allophanoyl-Derivat;
propan-1-ol
71-23-8

propan-1-ol

tachysterol
115-61-7

tachysterol

sodium

sodium

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

toxisterol2 R
104396-98-7

toxisterol2 R

ethanol
64-17-5

ethanol

tachysterol
115-61-7

tachysterol

sodium

sodium

A

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

B

toxisterol2 R
104396-98-7

toxisterol2 R

(2E)-2-<(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethanol
142980-92-5

(2E)-2-<(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethanol

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 3 steps
2: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
3: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
(2E)-ethyl <(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethanoate
142980-91-4

(2E)-ethyl <(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethanoate

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 99 percent / diisobutylaluminium hydride / toluene / 1 h / -78 °C
3: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
4: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
(2E)-<2-<(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethyl>diphenylphosphine oxide
141277-81-8

(2E)-<2-<(2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-2'-methylcyclohexylidene>ethyl>diphenylphosphine oxide

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
2: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
ethyl <(1'R,2'S,5'S)-1',5-'dihydroxy-2'-methylcyclohexyl>ethanoate
142980-89-0

ethyl <(1'R,2'S,5'S)-1',5-'dihydroxy-2'-methylcyclohexyl>ethanoate

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 90 percent / imidazole / dimethylformamide / 24 h
2: 93 percent / bis<2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethoxy>diphenylsulfurane / CCl4 / 70 h / Ambient temperature
3: 99 percent / diisobutylaluminium hydride / toluene / 1 h / -78 °C
5: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
6: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
ethyl <(1'R,2'S,5'S)-6-hydroperoxy-2',6-'dimethylbicyclo<3.2.1>-7'-oxaoctyl>ethanoate
142980-87-8, 143060-75-7

ethyl <(1'R,2'S,5'S)-6-hydroperoxy-2',6-'dimethylbicyclo<3.2.1>-7'-oxaoctyl>ethanoate

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 85 percent / pyridine, DMAP / CH2Cl2 / a) 0 deg C, 1 h, b) r.t., 2 h, c) reflux, 12 h
2: 87 percent / 0.2 M NaOEt / ethanol / 3 h / 0 °C
3: 90 percent / imidazole / dimethylformamide / 24 h
4: 93 percent / bis<2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethoxy>diphenylsulfurane / CCl4 / 70 h / Ambient temperature
5: 99 percent / diisobutylaluminium hydride / toluene / 1 h / -78 °C
7: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
8: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
ethyl <(1'R,2'S,5'S)-5'-acetoxy-1'-hydroxy-2'-methylcyclohexyl>ethanoate
142980-88-9

ethyl <(1'R,2'S,5'S)-5'-acetoxy-1'-hydroxy-2'-methylcyclohexyl>ethanoate

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 87 percent / 0.2 M NaOEt / ethanol / 3 h / 0 °C
2: 90 percent / imidazole / dimethylformamide / 24 h
3: 93 percent / bis<2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethoxy>diphenylsulfurane / CCl4 / 70 h / Ambient temperature
4: 99 percent / diisobutylaluminium hydride / toluene / 1 h / -78 °C
6: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
7: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
ethyl <(1'R,2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-1'-hydroxy-2'-methylcyclohexyl>ethanoate
142980-90-3

ethyl <(1'R,2'S,5'S)-5'-<(tert-butyldimethylsilyl)oxy>-1'-hydroxy-2'-methylcyclohexyl>ethanoate

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 93 percent / bis<2,2,2-trifluoro-1-phenyl-1-(trifluoromethyl)ethoxy>diphenylsulfurane / CCl4 / 70 h / Ambient temperature
2: 99 percent / diisobutylaluminium hydride / toluene / 1 h / -78 °C
4: 85 percent / n-butyl lithium / hexane; tetrahydrofuran / a) -78 deg C, 30 min, b) -70 deg C, 2 h, c) to r.t., 2 h
5: 86 percent / tetra-n-butylammonium fluoride / tetrahydrofuran / 1 h / Ambient temperature
View Scheme
Ergosterol
57-87-4

Ergosterol

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Irradiation.UV-Licht
2: sodium; N-methyl-aniline
View Scheme
Multi-step reaction with 2 steps
1: benzene / Irradiation.mit UV-Licht (Magnesium-Funken); Isolierung ueber das O-<3.5-Dinitro-4-methyl-benzoyl>-Derivat oder ueber das O-Acetyl-Derivat des Citraconsaeure-anhydrid-Addukts
2: sodium; ethanol / Isolierung als O-Allophanoyl-Derivat
View Scheme
pyridine
110-86-1

pyridine

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

acetic anhydride
108-24-7

acetic anhydride

(3S,5E,7E,10S)-3-acetoxy-9,10-seco-ergosta-5,7,22t-triene
71045-54-0

(3S,5E,7E,10S)-3-acetoxy-9,10-seco-ergosta-5,7,22t-triene

Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

cyclohexanone
108-94-1

cyclohexanone

(6Ξ,10S)-9,10-seco-8ξ-ergosta-4,6,22t-trien-3-one semicarbazone

(6Ξ,10S)-9,10-seco-8ξ-ergosta-4,6,22t-trien-3-one semicarbazone

Conditions
ConditionsYield
With aluminum isopropoxide; toluene Behandeln des Reaktionsprodukts mit Semicarbazid-hydrochlorid und Kaliumacetat in wss. Methanol;
Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one
55812-80-1, 55870-05-8, 70144-73-9

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
2: CrO3; acetic acid
View Scheme
Dihydrotachysterol2
67-96-9

Dihydrotachysterol2

2,3,3a,4,5,6,7,7aβ-octahydro-7aα-methyl-1R-(1α,1R,4R,5-trimethyl-2E-hexenyl)-4H-inden-4-one semicarbazide
2234-73-3

2,3,3a,4,5,6,7,7aβ-octahydro-7aα-methyl-1R-(1α,1R,4R,5-trimethyl-2E-hexenyl)-4H-inden-4-one semicarbazide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
2: CrO3; acetic acid
View Scheme

67-96-9Relevant articles and documents

A Convergent Approach to the Dihydrotachysterol Diene System. Application to the Synthesis of Dihydrotachysterol2 (DHT2), 25-Hydroxydihydrotachysterol2 (25-OH-DHT2), 10(R),19-dihydro-(5E)-3-epivitamin D2, and 25-Hydroxy-10(R),19-dihydro-(5E)-3-epivitamin D2

Maestro, Miguel A.,Castedo, Luis,Mourino, Antonio

, p. 5208 - 5213 (2007/10/02)

Total synthesis of A-ring fragments of 10(S),19-dihydrovitamins D and 10(R),19-dihydro-(5E)-epivitamins D from (+)-(S)-carvone and (-)-(R)-carvone is described.These fragments were used for convergent synthesis of dihydrotachysterol2 (DHT2), 25-hydroxydihydrotachysterol2, 10(R),19-dihydro-(5E)-3-epivitamin D2, and 25-hydroxy-10(R),19-dihydro-(5E)-3-epivitamin D2.

Hydrotitanation-Protonation of Vitamin D2 and Its Analogues: An Efficient Method for the Preparation of 10,19-Dihydrovitamins D2 Including Dihydrotachysterol2

Cota, J. G.,Meilan, M. C.,Mourino, A.,Castedo, L.

, p. 6094 - 6099 (2007/10/02)

In this study we describe an easy and efficient method for the preparation of the known 10,19-dihydrovitamins D2 2b (DHV2-II), 2c (DHV2-IV), 3c (dihydrotachysterol2, DHT2), and the new dihydrovitamins D2 2f and 2g.This method is based on the regioselective hydrometalation reaction of vitamin D2 and its derivatives with the system Cp2TiCl2-LiAlH4 or Cp2TiCl2-Red-Al (Aldrich).Under optimal conditions, the reaction with the former of these hydrometalating systems takes place with a high degree of stereoselectivity and allows labelling at C-19.

Administration of biologically active vitamin D3 and vitamin D2 materials

-

, (2008/06/13)

A process for administering biologically active vitamin D3 and vitamin D2 materials into the blood system of a subject by providing the biologically active vitamin D3 or D2 material to the skin whereby the skin releases the biologically active vitamin D3 or D2 material into the blood system in a controlled and prolonged manner.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 67-96-9